Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus CARTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus CARTIA XT.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs CARTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker